



## **SuperGen Names Mohammad Azab, M.D., Chief Medical Officer**

DUBLIN, Calif., Jul 21, 2009 (BUSINESS WIRE) -- SuperGen Inc. (Nasdaq:SUPG) announced today the addition of Mohammad Azab, M.D., M Sc, MBA to the management team as Chief Medical Officer. Dr. Azab will manage SuperGen's clinical development strategy, clinical operations, regulatory affairs, quality, and safety departments to advance the Company's oncology product portfolio from discovery through clinical Proof of Concept. His responsibilities will include the design and execution of clinical trials, including the recently commenced Phase I study of the first-in-class PIM Kinase Inhibitor, SGI-1776.

With more than 20 years of experience in worldwide drug development, clinical research, and medical affairs, resulting in eight approved drugs, including six in oncology, Dr. Azab brings extensive, international development and translational medicine expertise to SuperGen. Most recently, he was President and CEO of Intradigm Corporation, a privately held Palo Alto, CA company developing siRNA cancer therapeutics. Previously, Dr. Azab served as Executive Vice President of Research and Development, and Chief Medical Officer, of Vancouver, British Columbia-based QLT Inc., where he led clinical development for now-approved drugs in oncology, gastro-intestinal, and ophthalmologic indications. Prior to this, he served as Oncology Drug Team Leader at UK-based Zeneca Pharmaceuticals, now Astra Zeneca, where he held responsibilities in global clinical development and regulatory submissions. In this capacity, he managed the approval of drugs for prostate, breast, colorectal, and lung cancer indications. Before Zeneca, Dr. Azab was an international medical manager in oncology at Sanofi Pharmaceuticals, now Sanofi-Aventis, in Gentilly, France.

"As SuperGen continues to advance its first-in-class oncology pipeline, Dr. Azab's clinical leadership and translational experience will enable our Company to efficiently develop and partner our product candidates," said James S.J. Manuso, Ph.D., Chairman, President and CEO of SuperGen. "We are delighted to have Mohammad on our team."

Regarding his appointment, Dr. Azab commented, "I look forward to leading the clinical and regulatory development of SuperGen's pipeline. The Company's CLIMB discovery process promises to deliver more first-in-class, targeted therapeutics in the years ahead, and I am honored to be in a position to help translate rapidly discoveries into approvable drugs."

Dr. Azab received his medical degree in 1979 from Cairo University. He practiced as a medical oncologist and received post-graduate training and degrees in oncology research and statistics from the University of Paris-Sud and the University of Pierre and Marie Curie in France. He has published more than 100 medical papers and abstracts. He is an active member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the European Society of Medical Oncology. Dr. Azab received an MBA, with Distinction, from the Richard Ivey School of Business, University of Western Ontario.

### **About SuperGen**

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit <http://www.supergen.com>.

### **Forward-Looking Statements**

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

SOURCE: SuperGen Inc.

SuperGen, Inc.  
Timothy L. Enns, 925-560-2810

SVP, Corporate Communications & Business Development

[tenns@supergen.com](mailto:tenns@supergen.com)

Susanna Chau, 925-560-2845

Investor Relations Manager

[schau@supergen.com](mailto:schau@supergen.com)